Check 35,000+ stocks against 26 valuation models and 37 quality factors

Shanghai Conant Optical Co Ltd (2276) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Shanghai Conant Optical Co Ltd HK$35.90, price HK$35.66, upside +0.7%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · HK

SC Some data Sep 27, 2026

Shanghai Conant Optical Co Ltd

2276 · HK

NeutralQuality growthThe stock looks roughly fairly valued with average quality.

·Fair value HK$35.90 · Fairly valued (+0.7%)

!Quality 54/100

!Mixed Growth (revenue 5y +14.9 %/yr)

✓Highly profitable · 25.5% net margin (TTM)

✓Low debt · generates free cash flow

✓1.0% dividend yield · Well covered

!Mixed vs. peers (6/14)

✓Wide moat 91/100

!Evidence only medium, so the estimate is less certain

!Weak on future: 8 out of 100

!Weak on dividend: 20 out of 100

26 models, one by oneBear HK$19.95 to bull HK$48.81 Growth analysisrevenue history, year by year Quality 54/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Shanghai Conant Optical Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

57‑month range HK$3.79 – HK$64.41 · fair‑value band HK$19.95 – HK$48.81 · the HK$35.66 price screens below the HK$35.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Shanghai Conant Optical Co in your weekly email

Every Wednesday you see whether Shanghai Conant Optical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shanghai Conant Optical Co., Ltd. manufactures and sells resin spectacle lenses in Mainland China, the Americas, Asia, Europe, Oceania, and Africa.

Shanghai Conant Optical Co., Ltd. manufactures and sells resin spectacle lenses in Mainland China, the Americas, Asia, Europe, Oceania, and Africa. The company offers personalized, customized, and standardized lenses, such as UV++ series, 1.74 series, single vison, student, progressive, hi-vex, business, specialty, and anti-fog lenses, as well as UV shield and gaming glasses. It also provides after-sales support services. The company serves spectacle lens brand owners and international ophthalmic optic companies. Shanghai Conant Optical Co., Ltd. was founded in 1996 and is headquartered in Shanghai, China.

Stock analysis

Shanghai Conant Optical Co Ltd (2276) currently trades at HK$35.66, while our model-based Fair Value estimate is HK$35.90, so the stock looks roughly fairly valued today (gap 0.7%).

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$27.59 per share, and 1 of the 26 models we run sit above the HK$35.66 price.

Bear case: the Asset-Based group reads lowest at HK$4.44, and 25 of the 26 models stay below the price. Evidence for this calculation is medium.

Scenario range: HK$19.95 (bear) to HK$48.81 (bull), the price of HK$35.66 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Shanghai Conant Optical Co Ltd reported revenue of 2.2B CNY in FY2025 versus 1.4B CNY in FY2021, a compound +12.7%/yr. Reported net income was 558M CNY in FY2025, compounding +32.0%/yr from FY2021.

Key figures

Market cap HK$16.6B (≈ $2.1B) · P/E ratio 25.5 · P/S ratio 6.49 · EPS (TTM) HK$1.40 · Dividend yield 1.0% · Net margin 25.5% · Return on equity 25.8% · Return on assets (EBIT) 16.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 45% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −38% fair-value upside, at 1%, 2276 screens cheaper than that median.

Fair Value models

Bear HK$19.95 Fair Value HK$35.90 Bull HK$48.81

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.1802 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$8.15 HK$12.81 HK$20.15 79

Growth DCF HK$8.02 HK$12.04 HK$17.93 78

Owner Earnings HK$10.92 HK$17.58 HK$28.05 75

All 26 models by family

DCF Models

FCF DCF HK$8.15 HK$12.81 HK$20.15 79

Owner Earnings HK$10.92 HK$17.58 HK$28.05 75

5Y Revenue Exit HK$10.96 HK$19.05 HK$30.32 71

5Y EBITDA Exit HK$14.19 HK$25.85 HK$40.86 73

5Y P/E Exit HK$16.99 HK$31.73 HK$49.06 69

10Y Revenue Exit HK$9.45 HK$16.38 HK$27.47 65

10Y EBITDA Exit HK$11.75 HK$20.98 HK$35.68 66

10Y P/E Exit HK$13.46 HK$24.96 HK$42.07 62

Earnings-Based

Graham-Dodd HK$9.16 HK$45.54 HK$62.82 64

Lynch FV HK$12.29 HK$17.56 HK$22.83 61

PEG = 1.0 HK$12.29 HK$17.56 HK$22.83 57

EPV HK$11.76 HK$13.14 HK$14.29 74

Dividend Discount

Gordon GGM HK$2.72 HK$4.89 HK$6.74 68

DDM Multi-Stage HK$2.72 HK$4.47 HK$5.23 67

Multiples

P/E Multiple HK$22.24 HK$29.65 HK$37.06 63

P/S Multiple HK$13.87 HK$18.49 HK$23.11 58

P/B Multiple HK$17.18 HK$22.91 HK$28.64 55

EV/EBIT HK$20.23 HK$26.42 HK$32.61 66

EV/EBITDA HK$19.10 HK$24.91 HK$30.72 67

EV/Revenue HK$12.76 HK$17.51 HK$22.27 54

Asset-Based

NCAV (Graham) HK$3.32 HK$4.44 HK$6.63 54

Growth DCF

Growth DCF HK$8.02 HK$12.04 HK$17.93 78

Rev-Margin DCF HK$10.96 HK$18.74 HK$29.00 71

Economic Profit

Residual Income HK$7.50 HK$10.14 HK$17.00 73

ROIC Compounder HK$12.97 HK$16.12 HK$19.89 72

Growth Earnings

Growth-Adj P/E HK$19.32 HK$27.59 HK$35.87 67

Open the full fair value analysis →

Notify me when 2276 reaches fair value

Put 2276 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 54/100

Of which business quality 54 · Market factors (momentum, volatility) 31

Profitability 70

Margins and returns on capital today

Quality Growth 46

Are margins and returns improving?

Cashflow 46

Earnings quality: real cash, not paper profit

Fin. Strength 92

Balance sheet, leverage, solvency risk

Investment 12

Disciplined investing over empire-building

Low Volatility 53

Calm price path (market factor)

Momentum 26

Price trend over the last 3–12 months (market factor)

52W Momentum 16

Distance to the 52-week high (market factor)

Net Issuance 26

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 91/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+6.1%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+11.9%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+14.9%

Start year 2020 (pandemic)

Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+14.4%

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.

+32.6%

Earnings growth per share plus dividend.

Earnings per share, growth per year+31.6%

Dividend (yield on the price)1.0%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 28%

2025 sits 56% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+30.2%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+19.5%

Yearly sales growth analysts expect, extended to five years.

After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +28.0% a year for the price and +17.5% for the forecasts.

Forecast 2026 (sales)+17.4%

Forecast 2027 (sales)+24.2%

Projected 2028 (sales)+21.4%

Projected 2029 (sales)+18.6%

Projected 2030 (sales)+15.9%

Watch 2276, get fair value alerts →

Compare Shanghai Conant Optical Co Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 201 stocks

Beats the industry median on 5/13 measures

Overall it trails its industry peers.

Valuation

Quality Score 54 · Below median

Fair Value upside +0.7% · Above median

Profitability

Return on equity (TTM) 25.8% · Top 25%

Return on assets 12.7% · Top 25%

Net margin (TTM) 25.5% · Top 25%

Operating margin (TTM) 28.2% · Top 25%

Growth and dividend

Revenue growth 1.6% · Below median

Dividend yield (TTM) 1.0% · Below median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 25.5× · Pricier than median

P/B 5.17× · Priciest 25%

P/S (TTM) 6.49× · Priciest 25%

P/FCF 58.6× · Priciest 25%

EV/EBITDA 19.8× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)34 · sector 23

FUTURE (revenue growth)8 · sector 31

PAST (return on equity)100 · sector 27

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)20 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$405.18	$348.72	−14%
EssilorLuxottica Société anonyme EL	€143.90	€158.29	+10%
Becton, Dickinson and Company BDX	$183.82	$104.73	−43%
Medline Inc MDLN	$34.70	$29.06	−16%
Alcon Inc ALC	$64.47	$40.13	−38%
West Pharmaceutical Services, Inc WST	$375.65	$137.81	−63%
Sartorius Stedim Biotech S.A DIM	€212.40	€54.82	−74%
Straumann Holding STMN	CHF 97.48	CHF 45.50	−53%
Sartorius Aktiengesellschaft SRT	€206.50	€42.05	−80%
Solventum Corporation SOLV	$89.50	$134.36	+50%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shanghai Conant Optical Co Ltd · Fair Value
HK$35.90 +1%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/2276" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Shanghai Conant Optical Co Ltd · Fair Value</span><br><b style="font-size:20px">HK$35.90</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+1%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Shanghai Conant Optical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2276

Frequently asked questions

Is Shanghai Conant Optical Co Ltd (2276) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of HK$35.90 versus a price of HK$35.66, about +1% upside (fairly valued).

What is the fair value of 2276?

Our model-based fair value for Shanghai Conant Optical Co Ltd is HK$35.90 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$35.66.

What is the quality score of 2276?

Shanghai Conant Optical Co Ltd has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Shanghai Conant Optical Co Ltd (2276)?

Our model-based price target is the fair value of HK$35.90 (as of Sep 27, 2026) from 26 valuation models. Cautious scenario HK$19.95, optimistic scenario HK$48.81. It is a calculation from audited fundamentals, not an analyst target.

What is the Shanghai Conant Optical Co Ltd stock forecast for 2026?

Our models put fair value at HK$35.90, about +1% upside versus a price of HK$35.66 (fairly valued). Cautious scenario HK$19.95, optimistic scenario HK$48.81. The calculation is refreshed regularly with new filings.

What is the revenue of Shanghai Conant Optical Co Ltd (2276)?

Shanghai Conant Optical Co Ltd reported trailing-twelve-month revenue of about 2.2B CNY (latest available figure, as of Sep 27, 2026).

Does Shanghai Conant Optical Co Ltd pay a dividend?

Shanghai Conant Optical Co Ltd currently shows a dividend yield of about 0.98% relative to its recent price (as of Sep 27, 2026).

What growth is priced into Shanghai Conant Optical Co Ltd (2276)?

For today's price to be fair in a discounted-cash-flow model, Shanghai Conant Optical Co Ltd would have to grow free cash flow by +30.2 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.9 % per year. As of Sep 27, 2026.

What discount rate (WACC) does the fair value of 2276 use?

Our models discount Shanghai Conant Optical Co Ltd at 10.3 %: a base by market capitalisation (small), damped by beta 0.29, country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shanghai Conant Optical Co Ltd that is +30.2 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.

How much growth has Shanghai Conant Optical Co Ltd (2276) delivered so far?

Over the past 5 years revenue at Shanghai Conant Optical Co Ltd grew +14.9 % a year. The price currently implies +30.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Shanghai Conant Optical Co Ltd (2276) growing?

The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Shanghai Conant Optical Co Ltd (+30.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Shanghai Conant Optical Co Ltd (2276)?

The free-cash-flow yield on the price is 1.70 %: that much free cash flow Shanghai Conant Optical Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Shanghai Conant Optical Co Ltd (2276)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Conant Optical Co Ltd it is HK$35.90 per share (as of Sep 27, 2026), against a price of HK$35.66. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is Shanghai Conant Optical Co Ltd stock overvalued or undervalued in 2026?

As of Sep 27, 2026, 2276 trades below its calculated fair value: price HK$35.66, fair value HK$35.90, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 2276?

No. The price is what the market pays today (HK$35.66); the fair value is what the company's own numbers justify (HK$35.90). For Shanghai Conant Optical Co Ltd the two are HK$0.2440 per share apart. That gap is exactly why we show both numbers side by side.

How much is Shanghai Conant Optical Co Ltd worth?

The market values Shanghai Conant Optical Co Ltd at about HK$16.6B (market capitalisation, as of Sep 27, 2026). Per share that is HK$35.66; our models calculate a fair value of HK$35.90 per share.

What do the bullish and bearish scenarios say about 2276?

Our models span a range for Shanghai Conant Optical Co Ltd: cautious scenario HK$19.95, base HK$35.90, optimistic HK$48.81 per share (as of Sep 27, 2026, price HK$35.66). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 2276?

Shanghai Conant Optical Co Ltd trades at a price-to-earnings ratio of 25.5 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$35.90 is built from several models across several years. Other multiples: P/B 5.2, P/S 6.5, EV/EBITDA 19.8.

How solid is the balance sheet of Shanghai Conant Optical Co Ltd (2276)?

Balance-sheet figures for Shanghai Conant Optical Co Ltd (as of Sep 27, 2026): return on equity 25.8%. They feed the Quality Score of 54/100, which measures business quality independently of the share price.

How far is 2276 from its 52-week high?

Shanghai Conant Optical Co Ltd trades at HK$35.66, about 45% below its 52-week high of HK$64.41 and 26% above the low of HK$28.36 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$35.90 is for.

Which stocks are comparable to Shanghai Conant Optical Co Ltd?

From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Shanghai Conant Optical Co Ltd stock attractive at the current price?

The data as of Sep 27, 2026: price HK$35.66, calculated fair value HK$35.90 (+1%), Quality Score 54/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 2276 calculated?

We run Shanghai Conant Optical Co Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$35.90, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.7 % above its aggregate fair value. Shanghai Conant Optical Co Ltd currently trades 1 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Shanghai Conant Optical Co Ltd (2276)?

The closing price on Sep 30, 2026 was HK$35.66. Our model-based fair value is HK$35.90, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Shanghai Conant Optical Co Ltd right now?

The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (HK$19.95 to HK$48.81) leaves room in how you read the outcome.

Key figures of Shanghai Conant Optical Co Ltd

How large is the market capitalisation of Shanghai Conant Optical Co Ltd (2276)?

The market capitalisation of Shanghai Conant Optical Co Ltd is HK$16.6B (≈ $2.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Shanghai Conant Optical Co Ltd (2276)?

The price-to-sales ratio of Shanghai Conant Optical Co Ltd is 6.49 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Shanghai Conant Optical Co Ltd (2276)?

Earnings per share at Shanghai Conant Optical Co Ltd are HK$1.40 (price ÷ EPS = P/E 25.5). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Shanghai Conant Optical Co Ltd (2276)?

The dividend yield of Shanghai Conant Optical Co Ltd is 1.0% (payout 25.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Shanghai Conant Optical Co Ltd (2276)?

The net margin of Shanghai Conant Optical Co Ltd is 25.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Shanghai Conant Optical Co Ltd (2276)?

The return on equity (ROE) of Shanghai Conant Optical Co Ltd is 25.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Shanghai Conant Optical Co Ltd (2276)?

On an EBIT basis the return on assets of Shanghai Conant Optical Co Ltd is 16.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Shanghai Conant Optical Co Ltd (2276)?

The operating margin of Shanghai Conant Optical Co Ltd is 28.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Shanghai Conant Optical Co Ltd (2276)?

Revenue at Shanghai Conant Optical Co Ltd is growing +1.6% versus a year earlier (3y avg +11.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Shanghai Conant Optical Co Ltd (2276)?

Earnings per share at Shanghai Conant Optical Co Ltd are growing +16.1% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Shanghai Conant Optical Co Ltd (2276) hold?

Shanghai Conant Optical Co Ltd holds more cash than debt, 390M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Shanghai Conant Optical Co Ltd in the live analysis

One click puts Shanghai Conant Optical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.